Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Filleul, Bertrand" or (type any "bookEditor journalEditor issueEditor" and editor="Filleu...

Add to list
Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?

Charles Van Praet (UGent) , Sylvie Rottey (UGent) , Fransien Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele, Thierry Gil, Peter Schatteman, Bertrand Filleul, et al.

(2017) CLINICAL GENITOURINARY CANCER. 15(4). p.502-508
Add to list
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

Emmanuel Seront, Sylvie Rottey (UGent) , Bertrand Filleul, Philippe Glorieux, Jean-Charles Goeminne, Vincent Verschaeve, Jean-Marie Vandenbulcke, Brieuc Sautois, Petra Boegner, Aline Gillain, et al.

(2016) BJU INTERNATIONAL. 118(3). p.408-415
Add to list
Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, et al.

(2016) ONCOLOGIST. 21(12). p.1416-e17
Add to list
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program

Charles Van Praet (UGent) , Sylvie Rottey (UGent) , Fransien Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele, Thierry Gil, Peter Schatteman, Bertrand Filleul, et al.

(2016) UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 34(6). p.254.e7-254.e13
Add to list
- Conference Paper
- C3
Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program

Sylvie Rottey (UGent) , Charles Van Praet (UGent) , Fransien Van Hende, Gino Pelgrims, Wim Demey, Filip Van Aelst, Wim Wynendaele, Thierry Gil, Peter Schatteman, Bertrand Filleul, et al.

(2015) JOURNAL OF CLINICAL ONCOLOGY. 33(15, suppl.).

Academic Bibliography

Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program

Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program

Contents

Support

Contact